model, we assumed that ASA reduced the risk of preterm preeclampsia by 61% but did not reduce the risk of term preeclampsia. Sensitivity analyses that varied these and other assumptions were performed to assess the model's robustness. Threshold analyses were performed to identify the costs and risks of ASA-related complications (e.g., gastrointestinal bleeding and respiratory sensitivity) at which the preferred strategy shifted. The primary outcome was the incremental cost effectiveness ratio (ICER) defined as the cost needed to avert one case of preeclampsia. An ICER less than 100,000 USD was considered cost-effective based on literature describing maternal and neonatal costs associated with preeclampsia. RESULTS: Under baseline estimates, universal ASA use is the dominant strategy (i.e., costs the least and provides the greatest health benefit). For every 100,000 women, universal ASA use would save $19,216,551 and result in 308 fewer cases of preeclampsia compared to ASA use guided by biomarker and ultrasound risk assessment (Table 1) . In univariate and multivariate analyses, the model was sensitive only to the probability of ASA administration. When ASA use in the universal strategy was below 55%, following USPSTF guidelines became more cost effective. Threshold analysis revealed that only when the rate of GI bleeding with ASA exceeded 0.94% or the rate of respiratory complications exceeded 38% was universal ASA no longer the dominant strategy. In a Monte Carlo analysis, universal ASA was the most cost-effective strategy in 89% of simulations. CONCLUSION: Universal aspirin administration, as compared to several other strategies for preeclampsia risk assessment and selected ASA use is a dominant strategy across a broad range of relevant probabilities.
745 Medicaid expansion through the Affordable Care Act: longer wait times for pregnant women with OUD Elizabeth A. Greener, Neil S. Seligman, Elaine L. Hill University of Rochester Medical Center, Rochester, NY OBJECTIVE: The goal of Medicaid expansion through the 2010 Affordable Care Act (ACA), implemented in 2014, is to improve access to behavioral health services, including treatment for substance use disorders (SUD). Early work has found that expansion significantly increased access and wait time for SUD treatment in the general population; minimal work has been done with pregnant women. Our objective is to evaluate the impact of Medicaid expansion through the ACA on wait time to treatment entry for pregnant women with opioid use disorder (OUD). STUDY DESIGN: Data were obtained from the 2003-2015 Treatment Episode Data Set, an administrative data system tracking admissions into SUD treatment facilities receiving federal funding accounting for approximately 83% of eligible admissions in the US, not including pharmacotherapy with buprenorphine. Analysis included pregnant and non-pregnant female admissions indicating opioids as a drug of choice (DOC). We used mixed linear models to conduct difference-in-differences estimation comparing expansion states to non-expansion states on wait time to treatment entry and methadone pharmacotherapy rates. RESULTS: 2,291,443 female treatment admissions indicated opioids as a DOC, 4.1% (101,569) of which were pregnant. By 2014, 30 states and DC had expanded Medicaid eligibility ranging from 5 to 80% Federal Poverty Level. When comparing expansion states to nonexpansion states, increases in Medicaid eligibility through the ACA were associated with longer wait times for treatment entry for pregnant women compared to non-pregnant women (Figure 1 ). After 2014, most pregnant women were able to initiate treatment within 1 day (non-expansion) to 4 (expansion) days (p<.0001). Across the study period, pregnant women had higher rates of methadone use (42%) compared to non-pregnant women (23%). After the 2014 ACA implementation, rates of pharmacotherapy with methadone for non-pregnant women in expansion states surpassed pregnant women in non-expansion states (Figure 2) . CONCLUSION: Medicaid expansion has increased treatment entry wait times, potentially due to increased demand. Additionally, rates of pharmacotherapy with methadone increased. Further work should explore buprenorphine utilization in the context of Medicaid expansion.
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